Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 3831 PK and Safety in Schizophrenia
NCT02804568Phase 1Completed
- Sponsor
- Alkermes
- Start
- Jun 2016
- Primary completion
- Aug 2016
- Countries
- 1
01
Overview
Phase 1, open-label trial of olanzapine + samidorphan in schizophrenia, sponsored by Alkermes. Started Jun 2016; status: completed.
02
Drugs
olanzapine + samidorphan
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02804568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02804568.